7729.TWO Steminent Biotherapeutics Inc.
- Market cap
- TWD 15.1B
- P/E
- -
- P/B
- 15.71x
- ROE
- -29.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7729.TWO undervalued?
Graham numberThe Graham number of Steminent Biotherapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Steminent Biotherapeutics Inc. fundamental analysis
No fundamental analysis for Steminent Biotherapeutics Inc. yet.
Steminent Biotherapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.
Full company profileSteminent Biotherapeutics Inc. financial statements
Steminent Biotherapeutics Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 51.5M | 2.12M | 636K | 941K | 0.00 | - |
| Gross Profit | 28.5M | -1.75M | -8.93M | -1.04M | -16.4M | - |
| Operating Income | -43.0M | -75.6M | -98.2M | -131M | -162M | -174M |
| EBITDA | -35.4M | -112M | -75.1M | -115M | -140M | -141M |
| Net Income | -55.2M | -124M | -85.5M | -129M | -159M | -174M |
| EPS | -0.99 | -3.52 | -1.92 | -2.90 | -2.84 | -2.57 |
| Balance Sheet | ||||||
| Total Assets | 100M | 280M | 236M | 594M | 437M | 698M |
| Total Liabilities | 113M | 35.2M | 72.1M | 101M | 82.0M | 97.3M |
| Shareholders' Equity | -13.0M | 244M | 164M | 493M | 355M | 601M |
| Cash & Short-term Investments | 40.8M | 231M | 153M | 452M | 217M | 499M |
| Total Debt | 26.8M | 19.2M | 55.2M | 75.4M | 63.8M | - |
| Cash Flow | ||||||
| Operating Cash Flow | -31.5M | -55.1M | -69.2M | -115M | -139M | -132M |
| Capital Expenditure | 0.00 | 600K | 2.51M | 27.7M | 88.4M | 7.76M |
| Free Cash Flow | -31.5M | -55.7M | -71.7M | -143M | -228M | -140M |
| Ratios | ||||||
| ROE | - | -50.8% | -52.3% | -26.2% | -44.8% | -29.0% |
| ROA | -55.1% | -44.4% | -36.3% | -21.8% | -36.4% | -24.9% |
| Net Profit Margin | -107.3% | -5,855.8% | -13,439.3% | -13,733.2% | - | - |
| Debt to Equity | - | 0.08x | 0.34x | 0.15x | 0.18x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Steminent Biotherapeutics Inc. dividends
Steminent Biotherapeutics Inc. has not paid dividends in the last 6 fiscal years.
Who owns Steminent Biotherapeutics Inc.
Ownership data of Steminent Biotherapeutics Inc. is not available yet.
Steminent Biotherapeutics Inc. company profile
- Company name
- Steminent Biotherapeutics Inc.
- Ticker
- 7729.TWO
- ISIN
- TW0007729006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 12, Wenhu Street, Taipei, Taiwan, 11445
- Phone
- 886 2 2627 9216
- Website
- steminent.com
About Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.
Steminent Biotherapeutics Inc. management
3- Ling-Mei WangChairman & GM
- Yi-Chih LoDirector of Finance & Corporate Governance Officer and Accounting Supervisor
- Mr. Jonathan KoSenior Vice President